A notable biochemical response was observed, with PSA levels declining from 19.94 ng/mL to 0.34 ng/mL over an eight-month period. This reinforces the potential benefit of multimodal treatment, although clinical and biochemical follow-up remains essential given PDA’s aggressive nature and recurrence risk. Here, KLK3 is linked to Patent ductus arteriosus.